New Amsterdam Pharma CO N.V. NAMS
We take great care to ensure that the data presented and summarized in this overview for NewAmsterdam Pharma Co N.V. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in NAMS
Top Purchases
Top Sells
About NAMS
Insider Transactions at NAMS
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 07
2025
|
Mark C. Mc Kenna |
BUY
Grant, award, or other acquisition
|
Direct |
6,960
+50.0%
|
-
|
|
Jan 07
2025
|
John W Smither |
BUY
Grant, award, or other acquisition
|
Direct |
6,960
+50.0%
|
-
|
|
Jan 07
2025
|
William Lewis |
BUY
Grant, award, or other acquisition
|
Direct |
6,960
+50.0%
|
-
|
|
Jan 07
2025
|
Louis G Lange |
BUY
Grant, award, or other acquisition
|
Direct |
6,960
+50.0%
|
-
|
|
Jan 07
2025
|
Kamp Hilde Johanna Van Der |
BUY
Grant, award, or other acquisition
|
Direct |
6,960
+50.0%
|
-
|
|
Jan 07
2025
|
Johannes Jacob Pieter Kastelein Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
34,000
+50.0%
|
-
|
|
Jan 07
2025
|
Michael H. Davidson Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
123,529
+50.0%
|
-
|
|
Jan 07
2025
|
Louise Frederika Kooij Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+50.0%
|
-
|
|
Jan 07
2025
|
Juliette Berangere Audet Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
14,000
+48.1%
|
-
|
|
Jan 07
2025
|
Douglas F Kling Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
44,000
+50.0%
|
-
|
|
Jan 07
2025
|
William A Jones Jr Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
43,000
+50.0%
|
-
|
|
Jan 07
2025
|
Mayur Ian Somaiya Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
38,000
+50.0%
|
-
|
|
Dec 30
2024
|
Nap B.V. For Growth |
SELL
Open market or private sale
|
Indirect |
29,846
-0.28%
|
$746,150
$25.54 P/Share
|
|
Dec 27
2024
|
Nap B.V. For Growth |
SELL
Open market or private sale
|
Indirect |
41,472
-0.39%
|
$1,036,800
$25.95 P/Share
|
|
Dec 26
2024
|
Nap B.V. For Growth |
SELL
Open market or private sale
|
Indirect |
33,438
-0.31%
|
$869,388
$26.01 P/Share
|
|
Dec 24
2024
|
Nap B.V. For Growth |
SELL
Open market or private sale
|
Indirect |
16,164
-0.15%
|
$404,100
$25.66 P/Share
|
|
Dec 23
2024
|
Nap B.V. For Growth |
SELL
Open market or private sale
|
Indirect |
25,132
-0.23%
|
$628,300
$25.49 P/Share
|
|
Dec 20
2024
|
Nap B.V. For Growth |
SELL
Open market or private sale
|
Indirect |
49,772
-0.23%
|
$1,244,300
$25.83 P/Share
|
|
Dec 19
2024
|
Nap B.V. For Growth |
SELL
Open market or private sale
|
Indirect |
56,506
-0.52%
|
$1,412,650
$25.45 P/Share
|
|
Dec 18
2024
|
Nap B.V. For Growth |
SELL
Open market or private sale
|
Indirect |
100,728
-0.46%
|
$2,618,928
$26.13 P/Share
|
Last 12 Months Summary
Buy / Acquisition
618K
Shares
From
18
Insiders
| Grant, award, or other acquisition | 346K shares |
|---|---|
| Open market or private purchase | 24.5K shares |
| Exercise of conversion of derivative security | 247K shares |
Sell / Disposition
1.42M
Shares
From
4
Insiders
| Payment of exercise price or tax liability | 11.2K shares |
|---|---|
| Open market or private sale | 1.41M shares |